Interestingly, while CD79B mutations are confined to MCD, BN2, and A53-DLBCL, mutations in the CD79A subunit are enriched in EZB-DLBCL, which is insensitive to NF-κB inhibition [80,101], suggesting qualitatively distinct roles of CD79A and CD79B mutations in lymphomagenesis. The gene discussed is CD79A; the disease is diffuse large B-cell lymphoma.